EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Resolving melanoma heterogeneity at single‐cell resolution: implications for target discovery and therapy resistance

Mo Jin iD, Jie Song iD, Yiqing Xin iD, Qiwen Tan iD, Ziyan Qin iD, Zhicheng Wang iD, Ling Zhang iD

British Journal of Pharmacology · 2026-11-06

DOI: 10.1111/bph.70742 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-11-06. Written by Mo Jin and 6 co-authors. Institution: College of Basic Medical Sciences, The Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Min…. 107 references. Funded by: the National Key R&D Program of China, National Natural Science Foundation of China, National Basic Research Program of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Melanoma is characterized by profound intra‐tumoural heterogeneity and a complex tumour microenvironment (TME), which are primary drivers of therapy resistance. Conventional bulk sequencing lacks the resolution to capture these cellular nuances. Single‐cell technologies, particularly single‐cell RNA sequencing (scRNA‐seq) and spatial multiomics, have fundamentally advanced our understanding of melanoma by enabling high‐resolution characterization of malignant cell states, immune ecosystems and tumour microenvironment interactions. In this review, we summarize recent advances in single‐cell multiomics studies of melanoma heterogeneity and therapy resistance, focusing on the identification of drug‐tolerant persister states, immune escape mechanisms and resistance‐associated cellular transitions. We further discuss how single‐cell approaches facilitate target discovery, biomarker development and the rational design of combination therapies. By integrating multiomics profiling, computational modelling and pharmacological validation, these technologies provide a framework for translating cellular‐level insights into precision therapeutic strategies. Finally, we highlight current challenges and future opportunities for clinical implementation of single‐cell‐guided approaches in refractory melanoma.

Subjects

Author keywords

intra‐tumoural heterogeneitymelanomasingle‐cell RNA sequencing (scRNA‐seq)target discoverytherapeutic resistance

Authors and institutions

  • College of Basic Medical Sciences, The Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China.
  • School of Public Health, Jilin University, Changchun, China.
  • School of Pharmaceutical Sciences, Jilin University, Changchun, China.
  • School of Life Sciences, Westlake University, Hangzhou, China.

ORCID profiles: Mo Jin, Jie Song, Yiqing Xin, Qiwen Tan, Ziyan Qin, Zhicheng Wang, Ling Zhang

Funding

  • the National Key R&D Program of China
  • National Natural Science Foundation of China
  • National Basic Research Program of China

Cite

APA

Jin, M., Song, J., Xin, Y., Tan, Q., Qin, Z., Wang, Z., & Zhang, L. (2026). Resolving melanoma heterogeneity at single‐cell resolution: implications for target discovery and therapy resistance. British Journal of Pharmacology. https://doi.org/10.1111/bph.70742

Vancouver

Jin M, Song J, Xin Y, Tan Q, Qin Z, Wang Z, et al. Resolving melanoma heterogeneity at single‐cell resolution: implications for target discovery and therapy resistance. British Journal of Pharmacology. 2026. doi:10.1111/bph.70742

BibTeX
@article{Jin2026,
  author = {Jin, Mo and Song, Jie and Xin, Yiqing and Tan, Qiwen and Qin, Ziyan and Wang, Zhicheng and Zhang, Ling},
  title = {Resolving melanoma heterogeneity at single‐cell resolution: implications for target discovery and therapy resistance},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70742}
}
Start for free →